Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The investigatores propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in patients requiring hospitalization for symptomatic "high risk" COVID19 disease as reflected by the presence of elevated hsTPN. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illness. Investigators hypothesize that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality and a key secondary objective to reduce the requirement for and/or duration of mechanical ventilation. Finally, as the hospital mortality for patients requiring mechanical ventilation is very high (50 to 80%), these patients will be eligible for COVID19 CP treatment as well, even in the absence of elevated hsTPN. Although considerable overlap of these populations has been observed (elevated hsTPN and requirement for mechanical ventilation) there is not 100% redundancy and it is hopeful that COVID19 CP may provide benefit to these critically ill patients.
Description: Reduce mortality of high risk COVID 19 disease compared with historic precedent cohorts (35-50%)
Measure: Reduce mortality Time: At Day 28Description: Reduce the duration of mechanical ventilation in high risk COVID 19 disease compared with historic precedent cohorts (30-60%)
Measure: Reduce requirement for mechanical ventilation. Time: At Day 28Description: Reduce the time a participant will remain on the ventilator.
Measure: Reduce the duration of mechanical ventilation. Time: At Day 28Description: Data on the number of participants with treatment related adverse events will be assessed to determine the safety and tolerability of convalescent plasma.
Measure: Review of treatment related adverse events. Time: At Day 28